Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Study on the Prognostic Assessment of Light Chain Type Cardiac Amyloidosis (AL-CA) Based on Multimodal Fusion Radiomics Model of 18F-FAPI PET/CT and 3D CMR

NCT07103863 is registered in ClinicalTrials.gov with Beijing Anzhen Hospital as lead sponsor.

NCT NCT07103863
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07103863 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Study on the Prognostic Assessment of Light Chain Type Cardiac Amyloidosis (AL-CA) Based on Multimodal Fusion Radiomics Model of 18F-FAPI PET/CT and 3D CMR
Lead sponsor
Beijing Anzhen Hospital
Phase
Observational
Overall status
Enrolling by invitation
Start date
February 13, 2025
Completion date
February 1, 2028
Enrollment
49 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

al amyloidosis (al), cardiac amyloidosis